Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma
Journal of Clinical Oncology · 2025
DOI: 10.1200/jco-24-01466 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Sandra P D'Angelo und 19 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Immunotherapy, Adoptive, Liposarcoma, Myxoid, Membrane Proteins. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE The cancer/testis antigen New York esophageal squamous cell carcinoma 1 (NY-ESO-1) is a promising target in myxoid/round cell liposarcoma (MRCLS). METHODS In this pilot study, we assessed the adoptive T-cell therapy NY-ESO-1c 259 T letetresgene autoleucel (lete-cel) in patients with human leukocyte antigen (HLA)-A*02:01–, HLA-A*02:05–, and/or HLA-A*02:06–positive advanced/metastatic NY-ESO-1–expressing MRCLS. Patients underwent a reduced-dose (cohort 1) or standard-dose (cohort 2) lymphodepletion regimen (LDR). The primary end point was investigator-assessed overall response rate (ORR). Safety was assessed through adverse event (AE) reports. Correlative biomarker analyses were performed post hoc. The trial is registered at ClinicalTrials.gov (identifier: NCT02992743 ). RESULTS Of 23 enrolled patients, 10 in cohort 1 and 10 in cohort 2 received lete-cel. Investigator-assessed ORR was 20% (95% CI, 2.5 to 55.6) and 40% (95% CI, 12.2 to 73.8), median duration of response was 5.3 months (95% CI, 1.9 to 8.7) and 7.5 months (95% CI, 6.0 to not estimable [NE]), and median progression-free survival was 5.4 months (95% CI, 2.0 to 11.5) and 8.7 months (95% CI, 0.9 to NE) in cohorts 1 and 2, respectively. AEs included cytokine release syndrome and cytopenias, consistent with T-cell therapy/LDR. Post hoc correlative biomarkers showed T-cell expansion and persistence in both cohorts. CONCLUSION To our knowledge, this study is the first demonstrating the clinical promise of lete-cel in HLA-/NY-ESO-1-positive patients with advanced MRCLS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
- Washington University in St Louis, St Louis, MO.
- The Ohio State University, Columbus, OH.
- University of Michigan, Ann Arbor, MI.
- GlaxoSmithKline, Collegeville, PA.
ORCID-Profile: Sandra P D'Angelo, Brian A Van Tine, David Liebner, Scott M Schuetze, William D Tap, Sophia Goodison, Stefan Zajic, Michael J Nathenson, Neeta Somaiah
Förderung
- NCI NIH HHS
Zitieren
APA
D'Angelo, S. P., Druta, M., Van Tine, B. A., Liebner, D., Schuetze, S. M., Tap, W. D., Preston, J., Goodison, S., D'Souza, J. W., Kapoor, G. S., Suchindran, S., Zajic, S., Bhaskar, A., Kaczynski, H., Kim, J., Klohe, E., Corigliano, E., Eleftheriadou, I., Nathenson, M. J., & Somaiah, N. (2025). Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco-24-01466
Vancouver
D'Angelo SP, Druta M, Van Tine BA, Liebner D, Schuetze SM, Tap WD, et al. Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma. Journal of Clinical Oncology. 2025. doi:10.1200/jco-24-01466
BibTeX
@article{DAngelo2025,
author = {D'Angelo, Sandra P and Druta, Mihaela and Van Tine, Brian A and Liebner, David and Schuetze, Scott M and Tap, William D and Preston, Jessica and Goodison, Sophia and D'Souza, Jimson W and Kapoor, Gurpreet S and Suchindran, Sunil and Zajic, Stefan and Bhaskar, Aishwarya and Kaczynski, Heather and Kim, Jaegil and Klohe, Erika and Corigliano, Ellie and Eleftheriadou, Ioanna and Nathenson, Michael J and Somaiah, Neeta},
title = {Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma},
journal = {Journal of Clinical Oncology},
year = {2025},
doi = {10.1200/jco-24-01466}
}
EUVIMED